Abstract
Introduction:
Tumor budding, a prognostic biomarker in stage II colon cancer, is traditionally evaluated using H&E staining. This study aimed to assess the prognostic significance of tumor budding using immunohistochemistry (IHC) in a contemporary cohort of stage II colon cancer patients.
Materials and methods:
Tumor budding was evaluated in a retrospective population-based cohort comprising 493 patient with stage II colon cancer using IHC, following the H&E-based guidelines proposed by the International Tumor Budding Consensus Conference. Correlation between H&E-based and IHC-based tumor budding was assessed using a four-tired scoring system that included a zero budding (Bd0) category. Survival analyses explored the prognostic significance.
Results:
IHC-based tumor budding evaluation yielded significantly higher bud counts compared to H&E (p<0.01). The IHC tumor bud count was on average 16 buds higher and the disparity between the staining methods escalated with increasing bud count. In total, 21 patients were identified as having a complete absence of tumor budding and categorized as Bd0 based on IHC. The Bd0 tumors were associated with significantly improved recurrence-free survival (HR=5.19, 95% CI 1.27-21.16, p=0.02) and overall survival (HR=4.47, 95% CI 1.10-18.27, p=0.04) in a multivariate analysis, when compared to tumors with budding. The Bd0 category demonstrated a 100% predictive value for the absence of recurrence.
Discussion and conclusion
IHC-based tumor budding evaluation in stage II colon cancer provides additional prognostic information. Our findings indicate that Bd0 tumors display a lower level of aggressiveness in colon cancer compared to tumors that exhibit any degree of budding. The absence of tumor budding is associated with a favorable prognosis and may serve as a potential marker for identifying patients with no risk of recurrence. This is significant in a clinical setting when making the decision regarding adjuvant chemotherapy.
Tumor budding, a prognostic biomarker in stage II colon cancer, is traditionally evaluated using H&E staining. This study aimed to assess the prognostic significance of tumor budding using immunohistochemistry (IHC) in a contemporary cohort of stage II colon cancer patients.
Materials and methods:
Tumor budding was evaluated in a retrospective population-based cohort comprising 493 patient with stage II colon cancer using IHC, following the H&E-based guidelines proposed by the International Tumor Budding Consensus Conference. Correlation between H&E-based and IHC-based tumor budding was assessed using a four-tired scoring system that included a zero budding (Bd0) category. Survival analyses explored the prognostic significance.
Results:
IHC-based tumor budding evaluation yielded significantly higher bud counts compared to H&E (p<0.01). The IHC tumor bud count was on average 16 buds higher and the disparity between the staining methods escalated with increasing bud count. In total, 21 patients were identified as having a complete absence of tumor budding and categorized as Bd0 based on IHC. The Bd0 tumors were associated with significantly improved recurrence-free survival (HR=5.19, 95% CI 1.27-21.16, p=0.02) and overall survival (HR=4.47, 95% CI 1.10-18.27, p=0.04) in a multivariate analysis, when compared to tumors with budding. The Bd0 category demonstrated a 100% predictive value for the absence of recurrence.
Discussion and conclusion
IHC-based tumor budding evaluation in stage II colon cancer provides additional prognostic information. Our findings indicate that Bd0 tumors display a lower level of aggressiveness in colon cancer compared to tumors that exhibit any degree of budding. The absence of tumor budding is associated with a favorable prognosis and may serve as a potential marker for identifying patients with no risk of recurrence. This is significant in a clinical setting when making the decision regarding adjuvant chemotherapy.
| Bidragets oversatte titel | Immunhistokemisk undersøgelse af tumor budding i stadium II tyktarmskræft - Bd0 som en prognostisk markør |
|---|---|
| Originalsprog | Engelsk |
| Artikelnummer | PS-24-032 |
| Tidsskrift | Virchows Archiv |
| Vol/bind | 485 |
| Udgave nummer | Suppl. 1 |
| Sider (fra-til) | S159 |
| Antal sider | 1 |
| ISSN | 0945-6317 |
| DOI | |
| Status | Udgivet - sep. 2024 |
| Begivenhed | 36th European Congress of Pathology - Florence, Italien Varighed: 7. sep. 2024 → 11. sep. 2024 |
Konference
| Konference | 36th European Congress of Pathology |
|---|---|
| Land/Område | Italien |
| By | Florence |
| Periode | 07/09/2024 → 11/09/2024 |